

**IN THE CLAIMS:**

Please add the following new claims:

*Sub P31*  
--121. A method of treating a patient having an epithelial skin condition, comprising topically applying to the skin of said patient, a therapeutically effective amount of a compound, wherein in an *in vitro* bioassay, said compound inhibits a Keratinocyte Growth Factor (KGF) protein having the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis.

122. The method of claim 121, wherein said compound comprises an active ingredient that is selected from the group consisting of an antibody, a fragment of an antibody, a DNA probe, heparin and a peptide that is based upon said antibody.

*EI*  
123. The method of claim 121, wherein said epithelial skin condition is psoriasis.

124. The method of claim 121, wherein said compound is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

125. The method of claim 121, wherein said bioassay is the BALB/MK bioassay.

*Sub P32*  
126. An method of treating a patient having an epithelial skin condition comprising administering to said patient a therapeutically effective amount of a compound to treat said condition, wherein in an *in vitro* assay, said compound inhibits a Keratinocyte Growth Factor protein having the amino acid sequence of Figure 7 from stimulating epithelial cell mitogenesis.

127. .The method of claim 126, wherein said compound comprises an active ingredient that is selected from the group consisting of an antibody, a fragment of an antibody, a DNA probe, heparin and a peptide that is based upon said antibody.

128. The method of claim 126, wherein said bioassay is the BALB/MK bioassay.